Etoposide-Loaded Colloidal Delivery Systems Based on Biodegradable Polymeric Carriers
- Authors: Merkulova M.A.1, Osipova N.S.1, Kalistratova A.V.1, Ermolenko Y.V.1, Gel’perina S.E.1
-
Affiliations:
- Mendeleev University of Chemical Technology of Russia, 125047, Moscow, Russia
- Issue: Vol 85, No 5 (2023)
- Pages: 593-618
- Section: Articles
- URL: https://journals.rcsi.science/0023-2912/article/view/137229
- DOI: https://doi.org/10.31857/S0023291223600463
- EDN: https://elibrary.ru/DPYRBT
- ID: 137229
Cite item
Abstract
The review is focused on the etoposide delivery systems based on colloidal carriers, i.e., nanoparticles and micelles made of synthetic and natural polymers. Etoposide, a topoisomerase II inhibitor, occupies an important place in the chemotherapy of a number of tumors; however, its use is often limited due to severe side effects. The application of colloidal delivery systems makes it possible to change the pharmacokinetic parameters of etoposide and increase its accumulation in tumors leading to an increase in the antitumor effect. Of particular interest are stimuli-sensitive systems that respond to specific conditions in the tumor microenvironment, which can significantly increase the selectivity of the drug.
Keywords
About the authors
M. A. Merkulova
Mendeleev University of Chemical Technology of Russia, 125047, Moscow, Russia
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
N. S. Osipova
Mendeleev University of Chemical Technology of Russia, 125047, Moscow, Russia
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
A. V. Kalistratova
Mendeleev University of Chemical Technology of Russia, 125047, Moscow, Russia
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
Yu. V. Ermolenko
Mendeleev University of Chemical Technology of Russia, 125047, Moscow, Russia
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
S. E. Gel’perina
Mendeleev University of Chemical Technology of Russia, 125047, Moscow, Russia
Author for correspondence.
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
References
- Hande K.R. Etoposide: Four decades of development of a topoisomerase II inhibitor // European Journal of Cancer. 1998. V. 34. № 10. P. 1514–1521. https://doi.org/10.1016/S0959-8049(98)00228-7
- Примерный перечень основных лекарственных средств, 21-й перечень, 2019 г. Копенгаген: Европейское региональное бюро ВОЗ; 2020. Лицензия: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/handle/10665/331990/WHO-EURO-2020-476-40211-53802-rus.pdf?sequence=1&isAllowed=y.
- Agrawal K. Etoposide // xPharm: The Comprehensive Pharmacology Reference. 2007. P. 1–5. https://doi.org/10.1016/B978-008055232-3.61729-5
- Slevin M.L. The clinical pharmacology of etoposide // Cancer. 1991. V. 67. № S1. P. 319–329. https://doi.org/10.1002/1097-0142(19910101)67: 1+<319::AID-CNCR2820671319>3.0.CO;2-D
- Montecucco A., Zanetta F., Biamonti G. Molecular mechanisms of etoposide // EXCLI Journal. Leibniz Research Centre for Working Environment and Human Factors. 2015. V. 14. P. 95–108. https://doi.org/10.17179/excli2014-561
- Baldwin E.L., Osheroff N. Etoposide, topoisomerase II and cancer // Current Medicinal Chemistry-Anti-Cancer Agents. 2005. V. 5. № 4. P. 363–372. https://doi.org/10.2174/1568011054222364
- Kroschinsky F.P., Friedrichsen K., Mueller J. et al. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas // Cancer Chemother. Pharmacol. 2008. V. 61. P. 785–790. https://doi.org/10.1007/s00280-007-0535-3
- Shah J.C., Chen J.R., Chow D. Preformulation study of etoposide: Identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide // Pharmaceutical Research. 1989. V. 6. P. 408–412. https://doi.org/10.1023/A:1015935532725
- Siderov J., Prasad P., De Boer R., Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide // British Journal of Cancer. 2002. V. 86. № 1. P. 12–13. https://doi.org/10.1038/sj.bjc.6600003
- Hoetelmans R.M.W., Schornagel J.H., ten Bokkel Huinink W.W., Beijnen J.H. Hypersensitvity reactions to etoposide // Annals of Pharmacotherapy. 1996. V. 30. № 4. P. 367–371. https://doi.org/10.1177/106002809603000409
- Bernstein B.J., Troner M.B. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide // Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1999. V. 19. № 8. P. 989–991. https://doi.org/10.1592/phco.19.11.989.31566
- Zhao W. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy // Nat. Prod. Rep. 2021. V. 38. № 3. P. 470–488. https://doi.org/10.1039/d0np00041h
- Махачева Ф.А., Валиев Т.Т. Особенности вторичного острого миелоидного лейкоза у детей // Онкогематология. 2020. Т. 15. № 4. С. 12–17. https://doi.org/10.17650/1818-8346-2020-15-4-12-17
- Zhang M., Hagan C.T., Foley H. et al. Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models // Acta Biomaterialia. 2021. V. 124. P. 327–335. https://doi.org/10.1016/j.actbio.2021.02.001
- Rafiyath S. M., Rasul M., Lee B., Wei G., Lamba G., Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis // Exp. Hematol. Oncol. 2012. V. 1. P. 1–10. https://doi.org/10.1186/2162-3619-1-10
- Фармакопея РФ. Требования к показателям качества и исследованию лекарственных средств на основе липосом, мицелл и лекарственных средств, содержащих покрытия из наночастиц. https://pharmacopoeia.ru/trebovaniya-k-pokazatelyam-kachestva-i-issledovaniyu-lekarstvennyh-sredstv-na-osnove-liposom-mitsell-ilekarsvtennyh-sredstv-soderzhashhih-pokrytiya-iz-nanochastits/#%D0%A0%D0%90%D0%97%D0%94%D0%95%D0%9B_2_%D0%A0%D0%B0%D0%B7%D1%80%D0%B0%D0%B1%D0%BE%D1%82%D0%BA%D0%B0_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2%D0%B5%D0%BD%D0%BD%D1%8B%D1%85_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%BE%D0%B2_%D0%BD%D0%B0_%D0%BE%D1%81%D0%BD%D0%BE%D0%B2%D0%B5_%D0%BC%D0%B8%D1%86%D0%B5%D0%BB%D0%BB_%D0%B1%D0%BB%D0%BE%D0%BA-%D1%81%D0%BE%D0%BF%D0%BE%D0%BB%D0%B8%D0%BC%D0%B5%D1%80%D0%BE%D0%B2 (обращение 20 июля 2022).
- US FDA. Drug Products, Including Biological Products, that Contain Nanomaterials. Guidance for Industry, April 2022. https://www.fda.gov/media/157812.
- Sindhwani S., Syed, A. M., Ngai J. et al. The entry of nanoparticles into solid tumours // Nature Materials. 2020. V. 19. № 5. P. 566–575. https://doi.org/10.1038/s41563-019-0566-2
- Malinovskaya J., Salami R., Valikhov M. et al. Supermagnetic human serum albumin (HSA) nanoparticles and PLGA-based doxorubicin nanoformulation: A duet for selective nanotherapy // Int. J. Mol. Sci. 2023. V. 24. P. 627.https://doi.org/10.3390/ijms24010627
- Yuan Z.Q., Chen W.L., You B.G. et al. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor // JCR. 2017. V. 268. P. 198–211. https://doi.org/10.1016/j.jconrel.2017.10.025
- Huang H.L., Lin W.J. Dual peptide-modified nanoparticles improve combination chemotherapy of etoposide and siPIK3CA against drug-resistant small cell lung carcinoma // Pharmaceutics. 2020. V. 12. № 3. P. 254. https://doi.org/10.3390/pharmaceutics12030254
- Bai J., Tian Y., Liu F. et al. Octreotide-conjugated core-cross-linked micelles with pH/redox responsivity loaded with etoposide for neuroendocrine neoplasms therapy and bioimaging with photoquenching resistance // ACS Appl Mater Interface. 2019. V. 11. № 20. P. 18111–18122. https://doi.org/10.1021/acsami.9b01827
- Kuo Y.C., Chang Y.H., Rajesh R. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)‑poly(ε‑caprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid // Mater. Sci. Eng. C. 2019. V. 96. P. 114–128. https://doi.org/10.1016/j.msec.2018.10.094
- Cohen Y., Levi M., Lesmes U., Margier M., Reboul E., Livney Y.D. Re-assembled casein micelles improve in vitro bioavailability of vitamin D in a Caco-2 cell model // Food & Function. 2017. V. 8. № 6. P. 2133–2141. https://doi.org/10.1039/c7fo00323d
- Naumenko V.A., Vlasova K.Y., Garanina A.S. et al. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors // ACS Nano. 2019. V. 13. № 11. P. 12599–12612. https://doi.org/10.1021/acsnano.9b03848
- Lin Q., Fathi P., Chen X. Nanoparticle delivery in vivo: A fresh look from intravital imaging // EBioMedicine. 2020. V. 59. P. 102958. https://doi.org/10.1016/j.ebiom.2020.102958
- Golombek S.K. et al. Tumor targeting via EPR: Strategies to enhance patient responses // Advanced Drug Delivery Reviews. 2018. V. 130. P. 17–38. https://doi.org/10.1016/j.addr.2018.07.007
- Kakkar A., Traverso G., Farokhzad O.C., Weissleder R., Langer R. Evolution of macromolecular complexity in drug delivery systems // Nat. Rev. Chem. 2017. V. 1. № 8. P. 0063. https://doi.org/10.1038/s41570-017-0063
- Mitchell M.J., Billingsley M.M., Haley R.M. et al. Engineering precision nanoparticles for drug delivery // Nat. Rev. Drug Discov. 2021. V. 20. № 2. P. 101–124. https://doi.org/10.1038/s41573-020-0090-8
- Takechi-Haraya Y., Ohgita T., Demizu Y., Saito H., Izutsu K.I., Sakai-Kato K. Current status and challenges of analytical methods for evaluation of size and surface modification of nanoparticle-based drug formulations // AAPS PharmSciTech. 2022. V. 23. № 5. P. 150. https://doi.org/10.1208/s12249-022-02303-y
- Nel A.E., Mädler L., Velegol D. et al. Understanding biophysicochemical interactions at the nano–bio interface // Nature Materials. 2009. V. 8. № 7. P. 543–557. https://doi.org/10.1038/nmat2442
- Skalickova S., Nejdl L., Kudr J. et al. Fluorescence characterization of gold modified liposomes with antisense N-myc DNA bound to the magnetisable particles with encapsulated anticancer drugs (doxorubicin, ellipticine and etoposide) // Sensors. 2016. V. 16. № 3. P. 290. https://doi.org/10.3390/s16030290
- Mehrabi M., Esmaeilpour P., Akbarzadeh A. et al. Efficacy of pegylated liposomal etoposide nanoparticles on breast cancer cell lines // Turk. J. Med. Sci. 2016. V. 46. № 2. P. 567–571. https://doi.org/10.3906/sag-1412-67
- Deng W., Chen W., Clement S. et al. Controlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation // Nat. Commun. 2018. V. 9. № 1. 2713. https://doi.org/10.1038/s41467-018-05118-3
- Varshosaz J., Hassanzadeh F., Sadeghi-Aliabadi H., Firozian F. Uptake of etoposide in CT-26 cells of colorectal cancer using folate targeted dextran stearate polymeric micelles // Biomed. Res. Int. 2014. V. 2014. https://doi.org/10.1155/2014/708593
- Qian W.Y., Sun D. M., Zhu R.R. et al. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release // Int. J. Nanomedicine. 2012. P. 5781–5792. https://doi.org/10.2147/IJN.S34773
- Zhu R., Wang Q., Zhu Y. et al. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer // Acta Biomaterialia. 2016. V. 29. P. 320–332. https://doi.org/10.1016/j.actbio.2015.10.029
- Snehalatha M., Venugopal K., Saha R.N. Etoposide-loaded PLGA and PCL nanoparticles I: Preparation and effect of formulation variables // Drug Delivery. 2008. V. 15. № 5. P. 267–275. https://doi.org/10.1080/10717540802174662
- Yadav K.S., Chuttani K., Mishra A.K. et al. Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: Characterization, drug-release, blood-clearance, and biodistribution studies // Drug Dev. Res. 2010. V. 71. № 4. P. 228–239. https://doi.org/10.1002/ddr.20365
- Yadav K.S., Sawant K.K. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation // Curr. Drug Deliv. 2010. V. 7. № 1. P. 51–64. https://doi.org/10.2174/156720110790396517
- Wang Z., Li Z., Zhang D. et al. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery // Drug Delivery. 2015. V. 22. № 1. P. 79–85. https://doi.org/10.3109/10717544.2013.871600
- Kuo Y.C., Lee C.H. Inhibition against growth of glioblastoma multiforme in vitro using etoposide-loaded solid lipid nanoparticles with ρ-aminophenyl-α-D-manno-pyranoside and folic acid // J. Pharm. Sci. 2015. V. 104. № 5. P. 1804–1814. https://doi.org/10.1002/jps.24388
- Kuo Y.C., Wang I.H. Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody-and tamoxifen-conjugated solid lipid nanoparticles // J. Drug Target. 2016. V. 24. № 7. P. 645–654. https://doi.org/10.3109/1061186X.2015.1132223
- Jin G.W., Rejinold N.S., Choy J.H. Multifunctional polymeric micelles for cancer therapy // Polymers. 2022. V. 14. № 22. P. 4839. https://doi.org/10.3390/polym14224839
- Ahmad I., Pandit J., Sultana Y. et al. Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study // Mater. Sci. Eng. C. 2019. V. 100. P. 959–970. https://doi.org/10.1016/j.msec.2019.03.060
- Zhu Y., Zhu R., Wang M. et al. Anti-metastatic and anti-angiogenic activities of core–shell SiO2@LDH loaded with etoposide in non-small cell lung cancer // Advanced Science. 2016. V. 3. № 11. P. 1600229. https://doi.org/10.1002/advs.201600229
- Jo M.J., Shin H.J., Yoon M.S. et al. Evaluation of pH-sensitive polymeric micelles using citraconic amide bonds for the co-delivery of paclitaxel, etoposide, and rapamycin // Pharmaceutics. 2023. V. 15. № 1. P. 154. https://doi.org/10.3390/pharmaceutics15010154
- Abdel-Bar H.M., Walters A.A., Wang J.T.W., Al-Jamal K.T. Combinatory delivery of etoposide and siCD47 in a lipid polymer hybrid delays lung tumor growth in an experimental melanoma lung metastatic model // Adv. Healthc. Mater. 2021. V. 10. № 7. P. 2001853. https://doi.org/10.1002/adhm.202001853
- Maleki H., Naghibzadeh M., Amani A. et al. Preparation of paclitaxel and etoposide co-loaded MPEG-PL-GA nanoparticles: An investigation with artificial neural network // J. Pharm. Innov. 2021. V. 16. P. 11–25. https://doi.org/10.1007/s12247-019-09419-y
- Maleki H., Najafabadi M.R.H., Webster T.J. et al. Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma // Int. J. Pharm. 2021. V. 604. P. 120722. https://doi.org/10.1016/j.ijpharm.2021.120722
- Kovshova T., Mantrov S., Boiko S. et al. Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: Synergistic cytotoxicity in brain tumour cells // J. Microencapsul. 2023. V. 40. № 4. P. 246–262. https://doi.org/10.1080/02652048.2023.2188943
- Lim C., Ramsey J.D., Hwang D. et al. Drug-dependent morphological transitions in spherical and worm-like polymeric micelles define stability and pharmacological performance of micellar drugs // Small. 2022. V. 18. № 4. P. 2103552. https://doi.org/10.1002/smll.202103552
- Rezvantalab S., Drude N.I., Moraveji M.K. et al. P-LGA-based nanoparticles in cancer treatment // Front. Pharmacol. 2018. V. 9. P. 1260. https://doi.org/10.3389/fphar.2018.01260
- Casalini T., Rossi F., Castrovinci A., Perale G. A Perspective on polylactic acid-based polymers use for nanoparticles synthesis and applications // Front. Bioeng. Biotechnol. 2019. V. 7. P. 259. https://doi.org/10.3389/fbioe.2019.00259
- Operti M.C., Bernhardt A., Grimm S. et al. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up // Int. J. Pharm. 2021. V. 605. P. 120807. https://doi.org/10.1016/j.ijpharm.2021.120807
- Park K., Otte A., Sharifi F. et al. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles // Journal of Controlled Release. 2021. V. 329. P. 1150–1161. https://doi.org/10.1016/j.jconrel.2020.10.044
- Callewaert M., Dukic S., Van Gulick L. et al. Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency // J. Biomed. Mater. Res. A. 2013. V. 101 A. № 5. P. 1319–1327. https://doi.org/10.1002/jbm.a.34442
- Saadati R., Dadashzadeh S. Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: In vitro and in vivo evaluation // Int. J. Pharm. 2014. V. 464. № 1–2. P. 135–144. https://doi.org/10.1016/j.ijpharm.2014.01.014
- Yadav K.S., Jacob S., Sachdeva G., Sawant K.K. Intracellular delivery of etoposide loaded biodegradable nanoparticles: Cytotoxicity and cellular uptake studies // J. Nanosci. Nanotechnol. 2011. V. 11. № 8. P. 6657–6667. https://doi.org/10.1166/jnn.2011.4225
- Rivas C.J.M., Tarhini M., Badri W. et al. Nanoprecipitation process: From encapsulation to drug delivery // Int. J. Pharm. 2017. V. 532. № 1. P. 66–81. https://doi.org/10.1016/j.ijpharm.2017.08.064
- Callewaert M., Dukic S., Van Gulick L. et al. Etoposide encapsulation in surface-modified poly (lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency // J. Biomed. Mater. Res. A. 2013. V. 101. № 5. P. 1319–1327. https://doi.org/10.1002/jbm.a.34442
- Kovshova T., Osipova N., Alekseeva A. et al. Exploring the interplay between drug release and targeting of lipid-like polymer nanoparticles loaded with doxorubicin // Molecules. 2021. V. 26. № 4. P. 831. https://doi.org/10.3390/molecules26040831
- Stipa P., Marano S., Galeazzi R. et al. Prediction of drug-carrier interactions of PLA and PLGA drug-loaded nanoparticles by molecular dynamics simulations // Eur. Polym. J. 2021. V. 147. P. 110292. https://doi.org/10.1016/j.eurpolymj.2021.110292
- Ермоленко Ю.В., Семёнкин А.С., Ульянова Ю.В., Ковшова Т.С., Максименко О.О., Гельперина С.Э. Роль гидролитической деградации полилактидных носителей при разработке нано- и микроразмерных лекарственных форм на их основе // Известия Академии наук. Серия химическая. 2020. Т. 8. С. 1416–1427.
- D’Souza S.A. Review of in vitro drug release test methods for nano-sized dosage forms // Advances in pharmaceutics. 2014. V. 2014. P. 1–12. https://doi.org/10.1155/2014/304757
- Pimple S., Manjappa A.S., Ukawala M., Murthy R.S.R. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: In vitro cell line study to ensure advantage of combination therapy // Cancer Nanotechnol. 2012. V. 3. P. 25–36. https://doi.org/10.1007/s12645-012-0027-y
- Yadav R., Kumar D., Kumari A. et al. Encapsulation of podophyllotoxin and etoposide in biodegradable poly-D,L-lactide nanoparticles improved their anticancer activity // J. Microencapsul. 2014. V. 31. № 3. P. 211–219. https://doi.org/10.3109/02652048.2013.834988
- Singh V., Sahebkar A., Kesharwani P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery // Eur. Polym. J. 2021. V. 158. P. 110683. https://doi.org/10.1016/j.eurpolymj.2021.110683
- Посыпанова Г.А., Горшкова Л.Б., Родина А.В. и др. Характеристика противоопухолевой активности полимерной формы этопозида в составе биодеградируемого сополимера молочной и гликолевой кислот // Химико-фармацевтический журнал. 2016. P. 45–49.
- Mitra M., Dilnawaz F., Misra R. et al. Toxicogenomics of nanoparticulate delivery of etoposide: Potential impact on nanotechnology in retinoblastoma therapy // Cancer Nanotechnol. 2011. V. 2. № 1–6. P. 21–36. https://doi.org/10.1007/s12645-010-0010-4
- Schaefer M.J., Singh J. Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres // Biomaterials. 2002. V. 23. № 16. P. 3465–3471. https://doi.org/10.1016/S0142-9612(02)00053-4
- Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective // Annu. Rev. Pharmacol. 2012. V. 52. P. 481–503. https://doi.org/10.1146/annurev-pharmtox-010611-134623
- Yadav K.S., Chuttani K., Mishra A.K., Sawant K.K. Effect of size on the biodistribution and blood clearance of etoposide-loaded PLGA nanoparticles // PDA J. Pharm. Sci. Technol. 2011. V. 65. № 2. P. 131–139.
- Snehalatha M., Kolachina V., Saha R.N. et al. Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton’s lymphoma tumor bearing mice // J. Pharm. Bioallied Sci. 2013. V. 5. № 4. P. 290–297. https://doi.org/10.4103/0975-7406.120081
- Sarfarazi A., Lee G., Mirjalili S.A. et al. Therapeutic delivery to the peritoneal lymphatics: Treatment benefits and future prospects // Int. J. Pharm. 2019. V. 567. P. 118456. https://doi.org/10.1016/j.ijpharm.2019.118456
- Lee G., Han S., Inocencio I., Cao E. et al. Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties // Mol. Pharm. 2019. V. 16. № 12. P. 4987–4999. https://doi.org/10.1021/acs.molpharmaceut.9b00855
- Malinovskaya Y., Melnikov P., Baklaushev V. et al. Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells // Int. J. Pharm. 2017. V. 524. № 1–2. P. 77–90. https://doi.org/10.1016/j.ijpharm.2017.03.049
- Kuo Y.C., Chen Y.C. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles // Int. J. Pharm. 2015. V. 479. № 1. P. 138–149. https://doi.org/10.1016/j.ijpharm.2014.12.070
- Lagas J.S., Fan L., Wagenaar E. et al. P-Glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide // Clin. Cancer Res. 2010. V. 16. № 1. P. 130–140. https://doi.org/10.1158/1078-0432.CCR-09-1321
- Kuplennik N., Lang K., Steinfeld R., Sosnik A. Folate receptor α-modified nanoparticles for targeting of the central nervous system // ACS Appl. Mater. Interface. 2019. V. 11. № 43. P. 39633–39647. https://doi.org/10.1021/acsami.9b14659
- Godse R., Rathod M., De A., Shinde U. Intravitreal galactose conjugated polymeric nanoparticles of etoposide for retinoblastoma // J. Drug Deliv. Sci. Technol. 2021. V. 61. P. 102259. https://doi.org/10.1016/j.jddst.2020.102259
- Pan J., Rostamizadeh K., Filipczak N., Torchilin V.P. Polymeric co-delivery systems in cancer treatment: An overview on component drugs' dosage ratio effect // Molecules. 2019. V. 24. № 6. P. 1035. https://doi.org/10.3390/molecules24061035
- Fatma S., Talegaonkar S., Iqbal Z. et al. Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: An in vitro, ex vivo and in vivo investigations // Drug Delivery. 2016. V. 23. № 2. P. 500–511. https://doi.org/10.3109/10717544.2014.923956
- Espinoza S.M., Patil H.I., San Martin Martinez E., Casañas Pimentel R., Ige P.P. Poly-ε-caprolactone (PCL), a promising polymer for pharmaceutical and biomedical applications: Focus on nanomedicine in cancer // Int. J. Polym. Mater. 2020. V. 69. № 2. P. 85–126. https://doi.org/10.1080/00914037.2018.1539990
- Kalita N.K., Bhasney S.M., Mudenur C. et al. End-of-life evaluation and biodegradation of poly(lactic acid)(PLA)/polycaprolactone (PCL)/microcrystalline cellulose (MCC) polyblends under composting conditions // Chemosphere. 2020. V. 247. P. 125875. https://doi.org/10.1016/j.chemosphere.2020.125875
- Vivek K., Harivardhan Reddy L., Murthy R.S.R. Comparative study of some biodegradable polymers on the entrapment efficiency and release behavior of etoposide from microspheres // Pharm. Dev. Technol. 2007. V. 12. № 1. P. 79–88. https://doi.org/10.1080/10837450601168581
- Kuo Y.C., Wang I.H. Using catanionic solid lipid nanoparticles with wheat germ agglutinin and lactoferrin for targeted delivery of etoposide to glioblastoma multiforme // J. Taiwan Inst. Chem. Eng. 2017. V. 77. P. 73–82. https://doi.org/10.1016/j.jtice.2017.05.003
- Xu Y., Tang L., Liu Y. et al. Dual-modified albumin-polymer nanocomplexes with enhanced in vivo stability for hepatocellular carcinoma therapy // Colloids Surf. B. 2021. V. 201. P. 111642. https://doi.org/10.1016/j.colsurfb.2021.111642
- Xie P., Yan J., Wu M. et al. CD44 potentiates hepatocellular carcinoma migration and extrahepatic metastases via the AKT/ERK signaling CXCR4 axis // Annals of Translational Medicine. 2022. V. 10. № 12. P. 689. https://doi.org/10.21037/atm-22-2482
- Spada A., Emami J., Tuszynski J.A., Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery // Mol. Pharm. 2021. V. 18. № 5. P. 1862–1894. https://doi.org/10.1021/acs.molpharmaceut.1c00046
- Manjushree M., Revanasiddappa H.D. Evaluation of binding mode between anticancer drug etoposide and human serum albumin by numerous spectrometric techniques and molecular docking // Chemical Physics. 2020. V. 530. P. 110593. https://doi.org/10.1016/j.chemphys.2019.110593
- Akdogan Y., Reichenwallner J., Hinderberger D. Evidence for water-tuned structural differences in proteins: An approach emphasizing variations in local hydrophilicity // PLOS One. 2012. V. 7. https://doi.org/10.1371/journal.pone.0045681
- Osipova N., Budko A., Maksimenko O. et al. Comparison of compartmental and non-compartmental analysis to detect biopharmaceutical similarity of intravenous nanomaterial-based rifabutin formulations // Pharmaceutics. 2023. V. 15. № 4. P. 1258. https://doi.org/10.3390/pharmaceutics15041258
- Elgohary M.M., Helmy M.W., Mortada S.M., Elzoghby A.O. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer // Nanomedicine. 2018. V. 13. № 17. P. 2221–2224. https://doi.org/10.2217/nnm-2018-0097
- Narayana R.V.L., Jana P., Tomar N. et al. Carboplatin- and etoposide-loaded lactoferrin protein nanoparticles for targeting cancer stem cells in retinoblastoma in vitro // IOVS. 2021. V. 62. № 14. P. 13. https://doi.org/10.1167/iovs.62.14.13
- Akbal Ö., Erdal E., Vural T. et al. Comparison of protein- and polysaccharide-based nanoparticles for cancer therapy: Synthesis, characterization, drug release, and interaction with a breast cancer cell line // Artificial Cells, Nanomedicine, and Biotechnology. 2017. V. 45. № 2. P. 193–203. https://doi.org/10.3109/21691401.2016.1170694
- Raval N., Maheshwari R., Shukla H. et al. Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer // Mater. Sci. Eng. C. 2021. V. 126. P. 112186. https://doi.org/10.1016/j.msec.2021.112186
- Hwang D., Ramsey J.D., Kabanov A.V. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval // Adv. Drug Deliv. Rev. 2020. V. 156. P. 80–118. https://doi.org/10.1016/j.addr.2020.09.009
- Mohanty A.K., Dilnawaz F., Mohanty C., Sahoo S.K. Etoposide-loaded biodegradable amphiphilic methoxy (poly ethylene glycol) and poly (epsilon caprolactone) copolymeric micelles as drug delivery vehicle for cancer therapy // Drug Delivery. 2010. V. 17. № 5. P. 330–342. https://doi.org/10.3109/10717541003720688
- Letchford K., Liggins R., Burt H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: Theoretical and experimental data and correlations // J. Pharm. Sci. 2008. V. 97. № 3. P. 1179–1190. https://doi.org/10.1002/jps.21037
- Chen L., Tan L., Zhang X. et al. Which polymer is more suitable for etoposide: A comparison between two kinds of drug loaded polymeric micelles in vitro and in vivo? // Int. J. Pharm. 2015. V. 495. № 1. P. 265–275. https://doi.org/10.1016/j.ijpharm.2015.08.043
- Ukawala M., Rajyaguru T., Chaudhari K. et al. Investigation on design of stable etoposide-loaded PEG-PCL micelles: Effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles // Drug Delivery. 2012. V. 19 № 3. P. 155–167. https://doi.org/10.3109/10717544.2012.657721
- Shin H.C., Alani A.W., Rao D.A., Rockich N.C., Kwon G.S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs // J. Control Release. 2009. V. 140. № 3. P. 294–300. https://doi.org/10.1088/1361-6528/aa66ba
- Tsend-Ayush A., Zhu X., Ding Y., Yao J., Yin L., Zhou J., Yao J. Lactobionic acid-conjugated TPGS nanoparticles for enhancing therapeutic efficacy of etoposide against hepatocellular carcinoma // Nanotechnology. 2017. V. 28. № 19. P. 195602. https://doi.org/10.1088/1361-6528/aa66ba
- Zhu X., Tsend-Ayush A., Yuan Z. et al. Glycyrrhetinic acid-modified TPGS polymeric micelles for hepatocellular carcinoma-targeted therapy // Int. J. Pharm. 2017. V. 529. № 1–2. P. 451–464. https://doi.org/10.1016/j.ijpharm.2017.07.011
- Varshosaz J., Hassanzadeh F., Sadeghi H., Firozian F., Mirian M. Optimization of self-assembling properties of fatty acids grafted to methoxy poly(ethylene glycol) as nanocarriers for etoposide // Acta Pharm. 2012. V. 62. № 1. P. 31–44. https://doi.org/10.2478/v10007-012-0006-1
- Mudhakir D., Sukmadjaja S.A., Yeyet C.S. Packaging the alkaloids of cinchona bark in combination with etoposide in polymeric micelles nanoparticles // Int. J. Pharm. Sci. 2012. V. 6. № 12. P. 685–689. https://doi.org/10.5281/zenodo.1327853
- Na H.S., Lim Y.K., Jeong Y.I., Lee H.S., Lim Y.J., Kang M.S., Cho C.S., Lee H.C. Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model // Int. J. Pharm. 2010. V. 383. № 1–2. P. 192–200. https://doi.org/10.1016/j.ijpharm.2009.08.041
- Lim C., Dismuke T., Malawsky D. et al. Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq–guided combination with sapanisertib // Sci. Adv. 2022. V. 8. № 4. P. eabl5838. https://doi.org/10.1126/sciadv.abl5838
- Wan X., Min Y., Bludau H., Keith A., Sheiko S.S., Jordan R., Wang A.Z., Sokolsky-Papkov M., Kabanov A.V. Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer // ACS Nano. 2018. V. 12. № 3. P. 2426–2439. https://doi.org/10.1021/acsnano.7b07878
- Kim J.-H., Emoto K., Iijima M., Nagasaki Y., Aoyagi T., Okano T., Sakurai Y., Kataoka K. Core-stabilized polymeric micelle as potential drug carrier: Increased solubilization of taxol // Polym. Adv. Technol. 1999. V. 10. № 11. P. 647–654. https://doi.org/10.1002/(SICI)1099-1581(199911)10: 11<647::AID-PAT918>3.0.CO;2-Y
- Wang F., Bronich T.K., Kabanov A.V., Rauh R.D., Roovers J. Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier // Bioconjug. Chem. 2005. V. 16. № 2. P. 397–405. https://doi.org/10.1021/bc049784m
- Wang F., Bronich T.K., Kabanov A.V., Rauh R.D., Roovers J. Synthesis and characterization of star poly(epsilon-caprolactone)-b-poly(ethylene glycol) and poly(L-lactide)-b-poly(ethylene glycol) copolymers: Evaluation as drug delivery carriers // Bioconjug. Chem. 2008. V. 19. № 7. P. 1423–1429. https://doi.org/10.1021/bc7004285
- Ukawala M., Rajyaguru T., Chaudhari K., Manjappa A.S., Murthy R.S.R., Gude R. EILDV-conjugated, etoposide-loaded biodegradable polymeric micelles directing to tumor metastatic cells overexpressing α4β1 integrin // Cancer Nanotechnology. 2011. V. 2. P. 133–145. https://doi.org/10.1007/s12645-011-0023-7
- Luiz M.T., Di Filippo L.D., Alves R.C. et al. The use of TPGS in drug delivery systems to overcome biological barriers // Eur. Polym. J. 2021. V. 142. P. 110129. https://doi.org/10.1016/j.eurpolymj.2020.110129
- Lagarrigue P., Moncalvo F., Cellesi F. Non-spherical polymeric nanocarriers for therapeutics: The effect of shape on biological systems and drug delivery properties // Pharmaceutics. 2023. V. 15. № 1. P. 32. https://doi.org/10.3390/pharmaceutics15010032
- Kennedy L., Sandhu J.K., Harper M.E., Cuperlovic-Culf M. Role of glutathione in cancer: From mechanisms to therapies // Biomolecules. 2020. V. 10. № 10. P. 1429. https://doi.org/10.3390/biom10101429
- Jo M.J., Shin H.J., Yoon M.S. et al. Evaluation of pH-sensitive polymeric micelles using citraconic amide bonds for the co-delivery of paclitaxel, etoposide, and rapamycin // Pharmaceutics. 2023. V. 15. № 1. P. 154. https://doi.org/10.3390/pharmaceutics15010154
- Varshosaz J., Hassanzadeh F., Sadeghi H., Firozian F., Mirian M. Effect of molecular weight and molar ratio of dextran on self-assembly of dextran stearate polymeric micelles as nanocarriers for etoposide // J. Nanomater. 2012. V. 2012. P. 120. https://doi.org/10.1155/2012/265657
- Agwa M.M., Abu-Serie M.M., Abdelmonsif D.A., Moussa N., Elsayed H., Khattab S.N., Sabra S. Vitamin D3/phospholipid complex decorated caseinate nanomicelles for targeted delivery of synergistic combination therapy in breast cancer // Int. J. Pharm. 2021. V. 607. 120965. https://doi.org/10.1016/j.ijpharm.2021.120965
- Carlberg C., Muñoz A. An update on vitamin D signaling and cancer // Seminars in Cancer Biology. 2022. V. 79. P. 217–230. https://doi.org/10.1016/j.semcancer.2020.05.018
- Gaber M., Elhasany K.A. et al. Co-administration of tretinoin enhances the anti-cancer efficacy of etoposide via tumor-targeted green nano-micelles // Colloids Surf. B. Biointerfaces. 2020. V. 192. P. 110997. https://doi.org/10.1016/j.colsurfb.2020.110997
- Alliot J., Theodorou I., Nguyen D.V., Forier C., Ducongé F., Grave E., Doris E. Tumor targeted micellar nanocarriers assembled from epipodophyllotoxin-based amphiphiles // Nanoscale. 2019. V. 11. № 19. P. 9756–9759. https://doi.org/10.1039/C9NR01068H
- Alliot J., Theodorou I., Ducongé F., Gravel E., Doris E. Polyamine transport system-targeted nanometric micelles assembled from epipodophyllotoxinamphiphiles // Chemical Communications. 2019. V. 55. № 99. P. 14968–14971. https://doi.org/10.1039/c9cc07883e
- Leonard A., Wolff J.E. Etoposide improves survival in high-grade glioma: A meta-analysis // Anticancer Research. 2013. V. 33. № 8. P. 3307–3315.
- Mehta A., Awah C.U., Sonabend A.M. Topoisomera-se II poisons for glioblastoma; Existing challenges and opportunities to personalize therapy // Frontiers in Neurology. 2018. V. 9. P. 459. https://doi.org/10.3389/fneur.2018.00459
- Lagas J.S., Fan L., Wagenaar E., Vlaming M.L., van Tellingen O., Beijnen J.H., Schinkel A.H. P-Glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide // Clin. Cancer Res. 2010. V. 16 № 1. P. 130–140. https://doi.org/10.1158/1078-0432.CCR-09-1321
- Bart J., Groen H.J., van der Graaf W.T., Hollema H., Hendrikse N.H., Vaalburg W., Sleijfer D.T., de Vries E.G. An oncological view on the blood−testis barrier // The Lancet Oncology. 2002. V. 3. № 6. P. 357–363. https://doi.org/10.1016/s1470-2045(02)00776-3